Viracta Therapeutics, Inc. (NASDAQ:VIRX) has announced the publication of clinical data from a Phase 1b/2 study of Nana-val in 55 patients with R/R EBV+ lymphoma. The results showed complete responses and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes. The all-oral Nana-val was well tolerated, with the most common adverse events being low-grade nausea, constipation, and reversible cytopenias. The data served as a catalyst for the advancement of Nana-val into the confirmatory NAVAL-1 trial.